stoxline Quote Chart Rank Option Currency Glossary
  
MannKind Corporation (MNKD)
4.19  0.08 (1.95%)    04-23 10:25
Open: 4.11
High: 4.25
Volume: 132,572
  
Pre. Close: 4.11
Low: 4.11
Market Cap: 1,133(M)
Technical analysis
2024-04-23 9:48:57 AM
Short term     
Mid term     
Targets 6-month :  5.45 1-year :  5.96
Resists First :  4.67 Second :  5.11
Pivot price 4.24
Supports First :  3.97 Second :  3.3
MAs MA(5) :  4.13 MA(20) :  4.32
MA(100) :  3.92 MA(250) :  4.11
MACD MACD :  -0.1 Signal :  -0.1
%K %D K(14,3) :  29.7 D(3) :  24.1
RSI RSI(14): 46.5
52-week High :  5.75 Low :  3.17
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ MNKD ] has closed above bottom band by 42.3%. Bollinger Bands are 21.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 4.27 - 4.29 4.29 - 4.31
Low: 4.05 - 4.08 4.08 - 4.1
Close: 4.07 - 4.11 4.11 - 4.15
Company Description

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity to adult and pediatric endocrinologists, and other healthcare providers for the treatment of hypothyroidism. The company has a license and collaboration agreement with United Therapeutics Corporation. It also has an agreement with NRx Pharmaceuticals to develop a dry powder formulation of ZYESAMI (aviptadil), a synthetic form of human vasoactive intestinal peptide to help protect cells against inflammatory conditions. MannKind Corporation was incorporated in 1991 and is headquartered in Westlake Village, California.

Headline News

Sat, 30 Mar 2024
Institutional investors may overlook MannKind Corporation's (NASDAQ:MNKD) recent US$105m market cap drop as long-term gains remain positive - Simply Wall St

Tue, 26 Mar 2024
MannKind Corp Announces CFO Transition and New Compensation Plan - TipRanks.com - TipRanks

Mon, 11 Mar 2024
What's Going On With MannKind Stock? - MannKind (NASDAQ:MNKD) - Benzinga

Sun, 03 Mar 2024
Analysts Just Made A Meaningful Upgrade To Their MannKind Corporation (NASDAQ:MNKD) Forecasts - Yahoo Finance

Sat, 02 Mar 2024
MannKind Corporation (NASDAQ:MNKD) Surges 35% Yet Its Low P/S Is No Reason For Excitement - Simply Wall St

Wed, 28 Feb 2024
MannKind Corporation (NASDAQ:MNKD) Q4 2023 Earnings Call Transcript - Yahoo Finance

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Outperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Outperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 271 (M)
Shares Float 266 (M)
Held by Insiders 1.5 (%)
Held by Institutions 50.3 (%)
Shares Short 30,760 (K)
Shares Short P.Month 35,750 (K)
Stock Financials
EPS -0.04
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) -0.92
Profit Margin -6 %
Operating Margin 18.1 %
Return on Assets (ttm) 1.7 %
Return on Equity (ttm) 0 %
Qtrly Rev. Growth 62.2 %
Gross Profit (p.s.) 0
Sales Per Share 0.73
EBITDA (p.s.) 0.05
Qtrly Earnings Growth 0 %
Operating Cash Flow 34 (M)
Levered Free Cash Flow -24 (M)
Stock Valuations
PE Ratio -105
PEG Ratio 0.8
Price to Book value -4.62
Price to Sales 5.71
Price to Cash Flow 33.35
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android